SpyGlass Pharma, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | — | $29.2M | $20.0M |
| SG&A Expense | — | $12.3M | $7.1M |
| Operating Income | — | $-41.4M | $-27.1M |
| Operating Margin | — | — | — |
| Interest Expense | — | — | — |
| Pretax Income | — | $-39.9M | $-29.2M |
| Income Tax Expense | — | $0 | $0 |
| Net Income | — | $-39.9M | $-29.2M |
| Net Margin | — | — | — |
| EPS (Basic) | — | $-17.98 | $-16.31 |
| EPS (Diluted) | — | $-17.98 | $-16.31 |
| Shares Outstanding (Basic) | 33.4M | 2.2M | 1.8M |
| Shares Outstanding (Diluted) | 33.4M | 2.2M | 1.8M |
| Dividends Per Share | — | — | — |